Wedbush Issues Positive Forecast for Alto Neuroscience (NYSE:ANRO) Stock Price

Alto Neuroscience (NYSE:ANRO) had its price objective upped by equities researchers at Wedbush from $24.00 to $26.00 in a report issued on Thursday,Benzinga reports. The firm presently has a “neutral” rating on the stock. Wedbush’s price objective indicates a potential downside of 10.71% from the stock’s previous close.

Several other analysts also recently commented on ANRO. Bank of America started coverage on Alto Neuroscience in a research note on Tuesday, May 5th. They issued a “buy” rating and a $35.00 target price for the company. BTIG Research upped their price target on Alto Neuroscience from $28.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday. Zacks Research lowered Alto Neuroscience from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 22nd. HC Wainwright reissued a “buy” rating on shares of Alto Neuroscience in a research note on Wednesday, June 17th. Finally, Wolfe Research began coverage on Alto Neuroscience in a report on Friday, May 22nd. They set an “outperform” rating for the company. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $36.62.

Alto Neuroscience Price Performance

Alto Neuroscience stock opened at $29.12 on Thursday. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -12.03 and a beta of 1.06. Alto Neuroscience has a 52-week low of $3.02 and a 52-week high of $29.70. The stock’s 50 day moving average price is $25.44 and its two-hundred day moving average price is $22.57. The company has a debt-to-equity ratio of 0.07, a quick ratio of 20.52 and a current ratio of 20.52.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.08. On average, equities analysts predict that Alto Neuroscience will post -3.14 earnings per share for the current year.

Hedge Funds Weigh In On Alto Neuroscience

A number of hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp purchased a new stake in shares of Alto Neuroscience in the second quarter worth approximately $2,014,000. GK Wealth Management LLC bought a new stake in Alto Neuroscience during the second quarter worth $226,000. Perceptive Advisors LLC raised its position in Alto Neuroscience by 12.6% in the 1st quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock valued at $45,182,000 after buying an additional 225,500 shares during the last quarter. Bank of America Corp DE raised its position in Alto Neuroscience by 131.5% in the 1st quarter. Bank of America Corp DE now owns 25,677 shares of the company’s stock valued at $577,000 after buying an additional 14,585 shares during the last quarter. Finally, Eversept Partners LP bought a new position in Alto Neuroscience during the 1st quarter valued at $2,814,000.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.